GlassScriptPhysician profile
Monjri M Shah
NPI 1275791592
$2,379.78
in general payments reported to CMS, 2019-2025
34 companies · $619 in 2025
The $619 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $92.67 · 2021: $368 · 2022: $349 · 2023: $265 · 2024: $581 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,464.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $338.24 | 2019-2025 | Keytruda, Lynparza |
| Intuitive Surgical, INC. | $268.76 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $265.51 | 2021-2025 | |
| Octapharma USA, INC. | $217.64 | 2022-2025 | Octagam Immune Globulin (Human) |
| Daiichi Sankyo INC. | $175.57 | 2023-2025 | Enhertu, Datroway |
| Caris Mpi, INC. | $136.02 | 2025 | Mi Cancer Seek |
| Karyopharm Therapeutics INC. | $109.64 | 2021-2024 | Xpovio |
| Eisai INC. | $90.19 | 2022-2023 | |
| Abbvie INC. | $80.51 | 2025 | |
| Astellas Pharma US INC | $64.82 | 2023-2025 | Xospata, Myrbetriq |
| Conmed Corporation | $55.91 | 2020-2023 | Airseal, Visiclear |
| Pharmacosmos Therapeutics INC. | $55.71 | 2021-2025 | Monoferric |
| Glaxosmithkline, LLC. | $54.07 | 2020-2022 | |
| Clovis Oncology, INC. | $45.41 | 2019 | |
| Seagen INC. | $33.63 | 2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $31.35 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $29.52 | 2022-2023 | |
| Taiho Oncology, INC. | $29.10 | 2020-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $28.84 | 2021-2023 | Imbruvica |
| Pharmaessentia USA Corporation | $26.05 | 2025 | Besremi |
| Recordati_rare_diseases_inc. | $21.74 | 2025 | Sylvant |
| Tesaro, INC. | $21.60 | 2019 | |
| Telix Pharmaceuticals | $21.18 | 2023 | Illuccix |
| Janssen Biotech, INC. | $18.36 | 2022 | |
| Acrotech Biopharma INC. | $18.05 | 2021 | |
| Novocure INC. | $17.56 | 2025 | Optune Lua (Novottf-200t) |
| Aveo Pharmaceuticals, INC. | $16.92 | 2022 | |
| Lilly USA, LLC | $16.57 | 2023 | Retevmo, Jaypirca, Verzenio |
| Fennec Pharmaceuticals, INC. | $15.96 | 2025 | Fyarro |
| Beone Medicines USA, INC. | $15.86 | 2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $15.85 | 2021 | |
| Myriad Genetic Laboratories, INC. | $15.74 | 2021 | |
| Celgene Corporation | $14.65 | 2022 | |
| Integra Lifesciences Corporation | $13.25 | 2024 | Integra, Surgimend, Omnigraft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monjri Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.